Winners of 2024 DEI Employer® Awards. 2024 DEI Employer® Awards. 2024 DEI Employer® Awards & Top 100 DEI Employer® SHANGHAI, CHINA, January 6, 2025 /EI ...

I-Mab has begun the new year with a pipeline pivot, pausing work on an asset that Sanofi bought into last year to focus on ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Hemophilia News Today compiled a summary of the 10 most read hemophilia stories of 2024, with links to the individual items.

In separate DLL3 antibody-drug conjugate (ADC) deals, Roche licensed from Innovent Biologics and Ideaya reached for Hengrui.

A new report from Renub Research forecasts that the diabetes device market in China will grow from US$6.22 billion in 2023 to US$12.74 billion by 2032, representing a compound annual growth rate (CAGR ...

In 2023, drug companies launched new medications at prices 35 percent higher than the year before. On January 1, Pfizer ...

DOVBLERON® was approved by China’s National Medical Products Administration (NMPA): 1) for the treatment of adult patients with locally advanced or metastatic ROS1-positive NSCLC who have previously ...

Alibaba to sell stake in China's hypermarket chain Sun Art. Brand prescription drugs to rise an average 4.5% in 2025. Cybertruck blast driver identified; link to New Orleans attacker growing ...

China's economy demonstrated remarkable resilience and adaptability in 2024 amid complex domestic and global landscapes. The ...

This will be Sanofi's largest single investment in China since entering the country in 1982. Sanofi has not been alone ...

Drugmakers plan to raise U.S. prices on at least 250 branded medications including Pfizer COVID-19 treatment Paxlovid, ...